Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company
Rhea-AI Summary
Gilead Sciences has been recognized as a Leading Inclusion Index Company by Seramount, highlighting its commitment to fostering connections, creating opportunities for underrepresented groups, and cultivating a sense of belonging. This prestigious acknowledgment places Gilead among 42 organizations receiving this distinction in 2024.
Gilead Sciences is a research-based biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for unmet medical needs. The company aims to transform and simplify care for people with life-threatening illnesses globally. With operations in over 35 countries and headquarters in Foster City, California, Gilead continues to make strides in both medical innovation and workplace inclusion.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GILD gained 2.87%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NORTHAMPTON, MA / ACCESSWIRE / September 10, 2024 / This year, we're among 42 organizations being recognized by Seramount as a Leading Inclusion Index Company. The recognition highlights the connections we foster, the opportunities we create for underrepresented groups and the sense of belonging we cultivate.
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on accesswire.com